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LIVING KIDNEY DONOR INFORMED CONSENT PRACTICES VARY
BETWEEN U.S. AND NON-U.S. CENTERS
Ami M. Parekh, Elisa J. Gordon, Amit X. Garg, Amy D. Waterman, Sanjay Kulkarni,
and Chirag R. Parikh. (Yale University School of Medicine, New Haven, CT).
ABSTRACT
Living kidney donation rates are increasing in the United States and
internationally. Major consensus statements on the care of living kidney donors
recommend communicating all potential health and psychosocial risks to donors. We
evaluated the degree of international variation in the process of informed consent of
potential donors during their evaluation.
Transplant professionals attending the 2006 World Transplant Congress
responded to a survey assessing their informed consent processes, donor evaluation and
risk communication to living donors. US based respondents were compared to non-US
respondents. There were 221 respondents from 177 transplant centers and 40 countries
(48% US respondents). Across US and non-US transplant centers, potential donors were
most likely to receive written material about living donor risk by mail prior to evaluation,
receive risk information in person during evaluation, have a psychosocial evaluation,
which usually lasted longer than 30 minutes, and sign an official donation consent form
presented to them by a surgeon or a nephrologist. Although over 75% of respondents
stated that donors received information about medical risks such as hypertension, chronic
kidney disease, and potential need for dialysis, there was less consistency regarding
whether or not respondents conveyed an increased risk of these medical complications to
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donors. Additionally, the financial and psychosocial costs associated with being a living
donor were inconsistently communicated to donors during the informed consent process.
Compared to non-US respondents, US respondents were more likely to use written
material and visual aids to convey risks to donors, have mandatory psychosocial
evaluations, and provide access to donor support groups. US transplant centers were also
more likely to discuss the possibility of the donor needing dialysis or a transplant if their
remaining kidney fails in the future, possible travel expenses and loss of work income
due to donation recovery. Conversely, the US respondents’ centers were less likely to
offer long-term follow up and to utilize nephrologists to obtain written donor consent for
donation.
As dependence on living organ donation increases best practices for informed
consent, donor evaluation and uniform risk conveyance need to be established. This may
be accomplished by using a model informed consent template to ensure that informed
consent from donors is consistently obtained.
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INTRODUCTION
Due to the shortage of deceased donor kidneys and the increasing use of living
donor kidneys from non-related and expanded criteria kidney donors1-3 , almost half of all
kidneys donated in the United States come from living donors and the rates of living
kidney donation internationally continue to increase.3, 4 The fundamental premise of
living kidney transplantation is that the benefits to the recipient and potential
psychosocial benefits to the donor significantly outweigh the possible health risks to the
donor. The long term benefits for the recipient of transplantation of a kidney from a
living donor are significantly better than the benefits of cadaveric transplantation.5
Despite the improved outcomes for recipients living donor kidney transplantation
challenges the core medical ethics principle, “first do no harm.”
However, to date, the lack of a national registry, which would track all kidney
donation outcomes, limits comprehensive understanding of the donor’s medical, financial
and psychosocial risks.6-15 Although the risks of living kidney donation appear to be
minimal, as with any major surgery there are some risks of donation.16 Additionally, if
anything were to happen to the remaining kidney, there would be no backup. Also, even
if kidney donation does not raise the risk of long-term medical problems such as
hypertension, kidney donors who develop hypertension for other reasons may be more
vulnerable to kidney damage from the high blood pressure. Additionally, it may be that
the absence of discovered problems with living kidney donation is a reflection of the
above average health of kidney donors17 which may change if centers begin using
expanded criteria donors.
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The ethical practice of medicine requires appropriate informed consent for
medical procedures. Requiring physicians to disclose information to their patients
regarding treatment preserves patient autonomy and self-determination by lessening the
information asymmetry that exists between patient and physician. Informed consent for
all medical procedures and treatment is especially necessary in today’s patient centered
practice of medicine where the patient is expected not only to comply with a physician’s
orders but to fully participate in his or her treatment decisions.
In the case of living kidney donation, informed consent is particularly important
since the donor does not receive any medical benefit from the procedure itself and
undertakes the possibility of surgical risks including undergoing anesthesia, wound
infection, and post operative bleeding; long term medical risks like earlier onset of
hypertension or end-stage renal disease; and short- and long-term psychological and
financial risks. Although some scientists believe there are possible benefits like increased
self-esteem for those who donate their kidneys, the data are not definitive, since
dissatisfied donors may not participate in follow-up research.2, 7, 14, 18, 19 Additionally some
research indicates that a significant portion of donors experience short term depression,
while a small percentage of donors, usually linked to a bad outcome for the recipient or
chronic pain, regret donation in the long term.20
Major consensus statements have been published to provide recommendations for
the care of live kidney donor.21, 22 There is consensus amongst transplant professionals
internationally that informed consent for a living kidney donor should include an accurate
conveyance of short-and long-term medical, psychosocial and financial risks and that all
steps are taken to minimize such risks.21, 22 However, to date, the informed consent
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process has not been standardized. Preliminary research has shown that physicians and
transplant staff at a subset of transplant centers vary in how risky they perceive living
donation to be and how they convey these risks to potential donors.3, 23-26 Since the
aforementioned consensus statements were published, no international research across
transplant centers has been conducted to assess what is being regularly communicated to
potential living donors and the degree to which global practice variations exist regarding
the evaluation and informed consent of living kidney donors. Significant variability may
indicate a need for further consensus building, practice translation and policy
development.
Therefore, we surveyed US and non-US transplant professionals attending the
World Transplant Congress about their informed consent practices with living donors and
compared how risk communication varied between them. We compared US to non-US
participants since currently approximately 50% of the world’s living kidney donations
occur in the US and because healthcare policy and medical culture in the US is
sufficiently different from most other countries to warrant this comparison.

METHODS
SURVEY DESIGN AND CONTENT
In order to design a comprehensive survey that was easy to complete, a thorough
review of the literature regarding living kidney donation was performed. The review
included materials on the short and long-term medical and psychosocial risks of living
kidney donation as well as materials on current informed consent practices by
professionals working in kidney transplant. Additionally, consensus statements and
guidelines regarding living kidney donor evaluation and consent were reviewed.
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Based on this research, a 19-question survey addressing both the methods of
conveying risk to potential kidney donors and the actual risk parameters conveyed to
potential donors was drafted. The survey was designed to consist primarily of closed
ended questions so as to ensure that the results were quantifiable. The survey was then
independently circulated to ten physicians at various transplant centers for feedback and
was modified accordingly. The survey was designed to take approximately ten minutes
for a participant to complete. This length was decided upon based on feedback in order to
ensure maximum participation and thus generalizability of results.
The survey measured health professional demographics, how the respondent
conveyed medical, psychosocial and financial risks to a potential donor and what risks
were conveyed during the informed consent process. The survey was divided into three
parts, namely A. Background, B. Risk Information and C. Informed Consent Practices.
Section B was further subdivided into 3 areas: (i) Medical Risks (ii) Financial Risks and
(iii) Psychosocial Risks. All questions were close ended with a built-in skip pattern. For
example, regarding medical risks, the respondent was asked to check what increase in
relative risk of hypertension was conveyed to the donor. They had a choice of checking
various boxes with relative risk increases or checking the “not discussed” box. For the
psychosocial evaluations, the participants were asked whether a psychosocial evaluation
was mandated for the donor. If so, they were asked what length of time was allocated for
such an evaluation. For this follow up question, they were given 4 choices, less than 15
minutes, 15 to 30 minutes, 30 to 60 minutes or greater than 60 minutes. For such
questions they were asked to only check one of the answer choices. For other questions,
such as what methods were used to convey potential risks to donors, the survey
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participants were asked to check all the responses that applied. The only open ended
questions in the survey were the demographic questions: name, contact, center location,
and how many donor interactions the respondent had in the past year.
The survey was approved by the Institutional Review Board at Yale University
Medical Center.

RESPONDENTS
In order to solicit a broad range and large sample of transplant professionals, we
assessed a variety of different survey distribution techniques including online survey
distribution, mail distribution, email distribution and in person distribution. Based on
conversations with a number of experts, we concluded that results were most reliable and
respondents were most likely to participate if surveys were given to them in person in a
place conducive to immediately filling out the survey. Therefore, we decided to solicit
survey participants at the largest gathering of transplant professionals to date, namely at
the World Transplant Conference in Boston in July 2006. This opportunity was unique in
that it brought together a variety of professionals such as nephrologists, transplant
surgeons, transplant nurses and center coordinators, from around the world. It was the
first time a joint international transplant conference was held - combining the annual
American Transplant Congress and the various conferences held by the International
Congresses of the Transplantation Society. It was co-sponsored by the American Society
of Transplant Surgeons (ASTS), The American Society of Transplant (AST) and The
Transplantation Society (TTS).
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In order to recruit survey participants, we decided individuals would be most
likely to complete surveys when registering onsite for the conference. Distributing the
surveys in the conference registration area allowed us to have a one on one conversation
with conference attendees in order to assess whether they were involved with living
kidney transplantation, in particular if they were involved in donor evaluation or
management. If they stated they worked with living kidney donors, they were invited to
fill out the survey. With the help of the conference administrators we were able to
provide participants with a table on which to fill the survey out and pencils for doing so.
If the participant stated they wanted more time to fill out the survey, they were instructed
to fill it out at their leisure and to return it in any of six drop boxes located throughout the
conference venue or to mail or fax the survey to us after they had completed it.
In addition to recruiting survey participants during onsite registration, we also
provided surveys to individuals attending any conference lectures having to do with
living kidney donation. In such instances individuals were instructed that they could
return their surveys at the end of the lecture in a box placed outside the lecture room or in
any of the drop boxes located throughout the venue. Alternatively, as with those
individuals recruited at registration, they were told they could return the surveys via mail
or fax. These two recruitment methods were employed to enable a representative sample
of conference attendees involved in living kidney donation to be surveyed. In both cases,
the respondents were not given any form of compensation.
Consent for study participation was presumed upon returning the survey. An
information sheet provided with the survey explained the purpose of the study and
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indicated that all responses would be confidential. Permission to distribute the survey at
the WTC was obtained from the Conference Planning Committee prior to the conference.

DATA COLLECTION
The surveys were returned in containers located throughout the conference center.
The survey also included instructions to mail or fax surveys back to us after the
conference. Of the 223 complete surveys we recovered, 220 were returned at the
conference, two were received by mail and one by fax. Two of the surveys returned could
not be used in the analysis, because only demographic data were provided. Five surveys
did not include country of origin and so could not be used in the comparative analysis.
Thus the analysis was done using 216 surveys. Each survey was assigned a unique
number in order to make the data confidential and the responses were entered into an
Excel spreadsheet. The data were checked independently by two people for any
typographical or data entry errors.

STATISTICAL ANALYSIS
Standard descriptive statistics were computed for all variables. To assess
differences between US and non-US respondents, chi-square tests were used for
dichotomous variables and the Wilcoxon Rank-Sum test was used for ordinal variables.
In cases where there were a small number of observations for dichotomous outcomes,
Fisher's exact test was used. Variables are listed in Table 3 and Table 4 along with the
results. Respondents from the same transplant center were treated independently such that
some centers may be represented greater than others (Table 1). All analyses were based
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on the respondent, not on the transplant center. All analyses were conducted using SAS
9.1 (SAS Institute Inc., Cary, NC, USA).

RESULTS
RESPONDENTS DEMOGRAPHICS & TIME SPENT INTERACTING WITH DONORS
The survey respondents (n=216) represented 40 countries and 177 transplant
centers. 48% (n=104) of the respondents were from US centers, representing 79 centers
from 29 states (Table 1). The number of respondents from the various states ranged from
1 (8 states) to 13 (PA); the number of centers per state represented ranged from 1 (11
states) to 11 (PA). The 112 participants from the other countries represented 98 centers.
The number of participants per country ranged from 1 (16 countries) to 15 (UK). The
number centers per country represented ranged from 1 (15 countries) to 11 (UK).
Table 1. Countries Represented by Survey Respondents
COUNTRIES (40)
USA
Argentina
Australia
Belgium
Brazil
Canada
China
Columbia
Denmark
Egypt
France
Germany
Greece
Guatemala
India
Indonesia
Ireland
Israel
Japan
Korea

# of respondents
n (%)
104 (47)
3 (1)
7 (3)
2 (1)
10 (5)
6 (3)
1 (<1)
2 (1)
1 (<1)
3 (1)
1 (<1)
10 (5)
1 (<1)
2 (1)
5 (2)
1 (<1)
1 (<1)
1 (<1)
2 (1)
2 (1)

# centers
n (%)
79 (45)
3 (2)
4 (2)
2 (1)
9 (5)
6 (3)
1 (1)
2 (1)
1 (1)
3 (2)
1 (1)
8 (5)
1 (1)
2 (1)
5 (3)
1 (1)
1 (1)
1 (1)
2 (1)
2 (1)
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Kuwait
Malaysia
Mexico
Netherlands
Norway
New Zealand
Peru
Philippines
Poland
Russia
Saudi Arabia
Singapore
Slovakia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
UK

2 (1)
1 (<1)
4 (2)
2 (1)
1 (<1)
4 (2)
1 (<1)
1 (<1)
4 (2)
1 (<1)
2 (1)
1 (<1)
1 (<1)
2 (1)
2 (1)
2 (1)
3 (1)
1 (<1)
1 (<1)
15 (7)

2 (1)
1 (1)
3 (2)
2 (1)
1 (1)
3 (2)
1 (1)
1 (1)
2 (1)
1 (1)
2 (1)
1 (1)
1 (1)
2 (1)
2 (1)
2 (1)
3 (2)
1 (1)
1 (1)
11 (6)

The majority of the survey respondents were physicians (78%) and nurses (11%).
38% of the respondents were nephrologists and 28% were transplant surgeons. 14% of
the respondents were transplant coordinators. Compared to non-US respondents, more
US transplant coordinators (26% v. 6%, p<0.001) and non-MDs (29% v. 10%, p<0.001)
completed the survey than their counterparts outside of the US (Table 2).
Most respondents (74%) spent greater than 20% of their time with living kidney
donors, with over a third of respondents (38%) spending greater than 70% of their time
with living kidney donors. Additionally, about a quarter of respondents (24%) was either
the chairperson or director of their transplant programs. US versus non-US respondents
did not differ in the nature or quantity of interactions with donors in the past year (Table
2). Together the respondents interacted with over 10,500 potential donors per year.
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Table 2: Demographics of Respondents: US v non-US.

Degree
MD (Physician)
RN (Nurse)
PA (Physician Assistant)
PhD (Doctorate)
Other
Profession
Nephrologist
Surgeon
Psychiatrist/Psychologist
Transplant Coordinator
Nurse
Other
Proportion of Professional’s
Time Spent with Living Kidney
Donors
>70%
20-70%
5 – 20%
<5%
# Donor Interactions in previous
year, median (range)

Respondents
(Total n per
question)
208

P
value

US
n (%)

Non-US
n (%)

70 (71)
21 (21)
2 (2)
1 (1)
4 (4)

99 (90)
3 (3)
0 (0)
1 (1)
7 (6)

<0.001

38 (40)
22 (23)
2 (2)
25 (26)
6 (6)
3 (3)

46 (48)
38 (40)
0 (0)
6 (6)
2 (2)
3 (3)

0.001

42 (41)
36 (35)
15 (15)
9 (9)

37 (35)
38 (36)
23 (22)
8 (8)

0.56

30 (3-425)

25 (0-400)

0.62

191

208

208

PROCESS OF DONOR EVALUATION AND CONVEYING RISKS
According to respondents, across US and non-US transplant centers, most
potential donors were sent written material about living donor risk by mail before
evaluation (88%). Most respondents conveyed risk information to donors in person
during the medical evaluation (98%). Additionally, many respondents provided risk
information to potential donors in writing (49%), over the telephone (13%) and by using
video/DVD (19%).
Overall 55% of respondents used greater than one method to convey risks to
donors. Survey respondents used a variety of terminology to convey risks to donors. 34%
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of respondents stated the primarily used qualitative terms when describing risks of
donation. 31% used absolute rates of risk, 16% used relative risk rates and 12% stated
that the type of terminology they used varied from one donor to the next.
A majority of the time, nephrologists or surgeons were involved in discussions
regarding the medical risks of donation (84%, 56%), and usually multiple individuals
discussed the medical risks of donation with the potential donor (56%). No respondent
stated that medical risks of donation were not discussed.
Transplant Coordinators or Social Workers generally discussed the financial risks
of donation with the donors (51%, 46%). 41% of respondents stated that financial risks
were discussed by more than one professional; however, 11% of the respondents stated
that financial risks were not discussed with donors.
Social Workers, Nephrologists and Psychiatrists or Psychologists were almost
equally responsible for discussing the psychosocial risks of donation (49%, 45%, 44%);
with 57% of respondents stating that more than one individual was responsible for
discussing the psychosocial risks of donation with the potential donor and 1% of
respondents stated that psychosocial risks were not discussed.
79% of respondents stated that their centers mandate psychosocial evaluations of
potential donors. These generally lasted longer than 30 minutes (81%).35% of
respondents stated that their evaluations lasted longer than 60 minutes. 43% of
respondents said these evaluations were done by social workers; 51% were done by either
psychiatrists or psychologists.
Overall, 69% of respondents stated that donors were asked to sign an official
donation consent form prior to donation presented to them by a non-resident surgeon or
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nephrologist (88%). 42% of respondents stated that their centers provided donors with
access to support groups and 81% said their centers provided donors with long term
follow up care. 89% of respondents say they discussed donor risks with recipients.
Regarding the comparative analysis, US respondents were more likely to report
sending donors written materials prior to donation (95% vs. 83%, p = 0.007), require
psychosocial evaluations of the potential donors (92% vs. 68%, p <0.0001), have
surgeons be responsible for obtaining written consent (74% vs. 50%, p < 0.001), and
offer donors a support group (54% v. 32%, p<0.002). In contrast, respondents from nonUS centers were more likely to report that donors receive long-term follow up (96% v.
64%; p <0.0001), and were more likely to sign a consent form specifically for organ
donation (77% v. 61%, p <0.01) and have nephrologists responsible for obtaining consent
(40% v. 5%, p<0.01). Psychosocial evaluations occurring at US and non-US transplant
centers varied considerably. In the US, respondents reported that social workers most
commonly conducted the psychosocial evaluation of potential donors (89% v. 41%,
p<0.01), with most of these evaluations taking longer than 30 minutes (91% v. 69%,
p<0.01).
Table 3. Process of Donor Evaluation and Informed Consent: US v. non-US

How medical risks are conveyed
Qualitative
Relative
Absolute
Varies
What methods are used to convey risks to potential
donors
In Person
By Telephone
Written Material
Video/DVD
Donor receives written material prior to donation

Overall
N (%)

US
n (%)

Non-US
n (%)

73 (36)
35 (17)
69 (34)
25 (12)

36 (37)
19 (19)
28 (29)
13 (13)

37 (35)
16 (15)
41 (39)
12 (11)

0.35

204 (98)
86 (41)
28 (13)
42 (20)

99 (100)
57 (58)
23 (23)
30 (30)

105 (95)
29 (45)
5 (5)
12 (11)

0.03
0.06
<0.0001
0.001

P value
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Yes
No
Mandatory psycho-social assessment of all potential
donors
Yes
No
Who is responsible for the psychosocial evaluation
Psychiatrist
Psychologist
Social Worker
How long is the evaluation
<15 minutes
15 – 30 minutes
30 – 60 minutes
> 60 minutes
Center provides donors access to a support group
Yes
No
Center provides long term follow up
Yes
No
Center has a specific consent form for live organ
donation
Yes
No
Who is the person responsible for obtaining consent
Nephrologist
Surgeon
Nurse/Nurse Practitioner
Social Worker
Nephrologist Trainee
Surgical Trainee
Donor nephrectomy risks are discussed with kidney
recipients
Yes
No
Center would adopt a centralized informed consent
template
Yes
No

184 (88)
24 (12)

92 (95)
5 (5)

92 (83)
19 (17)

0.007

167 (80)
43 (20)

92 (92)
8 (8)

75 (68)
35 (32)

<0.0001

76 (44)
71 (41)
117 (68)

36 (38)
34 (36)
85 (89)

40 (51)
28 (36)
32 (41)

0.08
0.54
<0.0001
0.004

5 (8)
28 (16)
77 (45)
60 (35)

0 (0)
9 (10)
50 (54)
34 (37)

4 (5)
19 (25)
27 (35)
26 (34)

84 (42)
115 (58)

50 (54)
43 (46)

34 (32)
72 (68)

0.002

171 (81)
41 (19)

65 (64)
37 (36)

106 (96)
4 (4)

<0.0001

145 (69)
64 (31)

59 (61)
38 (39)

86 (77)
26 (23)

0.012

48 (24)
124 (62)
26 (13)
8 (4)
5 (3)
7 (4)

5 (5)
70 (74)
18 (19)
0 (0)
1(1)
4 (4)

43 (40)
54 (50)
8 (7)
8 (7)
4 (4)
3 (3)

<0.0001
0.0007
0.015
0.007
0.22
0.59

185 (89)
24 (11)

84 (83)
17 (17)

101 (93)
7 (7)

0.085

159 (81)
37 (19)

77 (79)
21 (21)

82 (84)
16 (16)

0.001

CONTENT OF RISK COMMUNICATION
More than 90% of respondents discussed multiple possible long-term medical
risks with living donors including: hypertension, proteinuria, premature death, premature
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cardiac disease, chronic kidney disease, and the possibility of needing dialysis or a
transplant, should their kidney fail in the future. However, respondents varied
considerably in whether or not they conveyed an increased risk for the donor as compared
to a non-donor. For example, 15% of respondents told donors there was no increased risk
of developing hypertension, 81% told them there was an increased risk and 4% did not
discuss hypertension with donors. There was similar variation with regards to
proteinuria: 15% stated there was no increased risk, 78% stated there was an increased
risk and 7% did not discuss the risk. The variation in medical risk conveyance was even
more pronounced for the risk of premature death and cardiac disease and the greatest for
the risk of future chronic kidney disease and the possible requirement of dialysis or
kidney transplant. For premature death, 66% of respondents stated no increased risk, 23%
stated an increased risk, and 11% did not discuss this risk; for premature cardiac disease,
61% stated no increased risk, 28% stated an increased risk post donation, and 10% did
not discuss this risk. For the increased risk of developing future chronic kidney disease
40% of respondents stated there was no increased risk with donation, 56% stated there
was an increased risk and 5% did not discuss this risk. Similarly, for the risk of requiring
dialysis or kidney transplantation in the future, while 48% of respondents stated that there
was no increased risk of requiring such measures, 46% stated that there was an increased
risk and 6% did not discuss this risk with donors.
Fewer respondents discussed specific financial risks with potential donors. Of the
five specific financial costs that donors may face that we listed, on average 41% of
respondents did not discuss the specific cost. Approximately two thirds of respondents
did discuss loss of salary, travel costs and family care costs, whereas increased costs of
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health insurance and rehabilitation were discussed by a little more than half of the
respondents. When the costs were discussed there was again great variability regarding
whether donors were told there would be no significant cost, or whether there were costs
associated with donation. For example, with regards to the costs of family care during the
donation process, 27% of respondents told donors there was no increased cost, 33% told
donors there was an increased cost and 39% of respondents did not discuss the cost at all.
Although 78% of respondents discussed the potential of future improved
psychosocial well being with their prospective donors (17% not discussed, 5 % stated
improved psychosocial well being was not likely), they were less likely to inform donors
about potentially negative psychosocial outcomes. For example, over a quarter of US
respondents did not discuss the potentially stressful nature of transplant (27%, not
discussed), the possibility of post-operative depression (24%) or suicidal ideation (36%),
or the possibility of adverse effects to the donor’s marital or family life (23%). If
psychosocial risks were discussed, some health professionals told living donors that they
were not likely to have these issues arise in their situation while others told donors that
these risks were somewhat likely. For example, while 30% of respondents told potential
donors that adverse effects on their marital/family life would not be likely, 48% of
respondents stated that such risks were likely.
Exploring differences in what risks were communicated to potential donors at US
and non-US transplant centers, US transplant professionals were more likely to
communicate to potential donors that they might have to go on dialysis or receive a
transplant if their remaining kidney failed (57% v. 36%; p =0.01), to discuss with donors
that they may have to pay travel costs to the transplant centers (63% v. 35%; p=0.001)
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and discuss possible lost income while they recovered (59% v. 40%; p=0.01). There were
no significant differences in the conveyance of psychosocial risks between US and nonUS respondents.
Table 4. Risks Communicated with Potential Donors: US v. non-US Respondents
Respondents
(total n per
question)
Medical Risks*

US
n (%)

Non-US
n (%)

Not
Increased

Increased

Not
Discussed

Not
Increased

Increased

Not
Discussed

P
Value

3 (3)

0.057

Hypertension

198

20 (21)

70 (74)

4 (4)

10 (10)

91 (88)

Proteinuria

197

17 (18)

69 (74)

7 (8)

13 (13)

85 (82)

6 (6)

0.44

Premature Death

199

60 (64)

27(29)

7 (7)

72 (69)

19 (18)

14 (14)

0.12

Premature Cardio
Vascular Disease

197

60 (64)

25 (27)

9 (10)

61 (59)

31 (30)

11 (11)

0.80

Chronic Kidney
Disease

196

35 (38)

54 (59)

3 (3)

43 (41)

55 (53)

6 (6)

0.58

Requirement of
Dialysis/Kidney
Transplant

197

37 (40)

52 (57)

3 (3)

58 (55)

38 (36)

9 (9)

P
Value

0.01

No Cost

Cost

Not
Discussed

No Cost

Cost

Not
Discussed

Travel Expenses

144

5 (8)

38 (63)

17 (28)

21 (25)

29 (35)

34 (40)

0.001

Loss of Work
Days

147

6 (10)

35 (59)

18 (31)

24 (27)

35 (40)

29 (33)

0.019

Family Care
Needs

142

16 (28)

18 (32)

23 (40)

23 (29)

29 (29)

33 (42)

0.95

Increased Cost of
Insurance

149

29 (43)

8 (12)

36 (45)

33 (43)

8 (11)

35 (46)

0.96

Rehabilitation
Costs

136

28 (44)

4 (6)

31 (49)

31 (42)

10 (14)

32 (44)

0.37

Total estimated
cost

111

6 (13)

17 (37)

23 (50)

11 (17)

25 (38)

29 (45)

0.80

Not
Likely

Somewhat
Likely

Not
Discussed

Not
Likely

Somewhat
Likely

Not
Discussed

Financial Costs

Psychosocial
Risks

P
Value

Improved Well
Being

171

4 (5)

58 (74)

16 (21)

5 (5)

75 (81)

13 (14)

0.53

Recollection of
time as
traumatic/stressful

164

12 (16)

38 (51)

25 (33)

24 (27)

45 (51)

20 (22)

0.14

Post Op
Depression

162

18 (24)

34 (46)

22 (30)

27 (31)

44 (50)

17 (19)

0.28

Suicidal Ideation

158

32 (44)

7 (10)

33 (46)

53 (62)

9 (10)

24 (28)

0.06

Marital/Familial
Life Adverse Eff.

164

17 (23)

35 (47)

22 (30)

32 (36)

43 (48)

15 (17)

0.07

* We did not define any of the medical risks in the survey.
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CONSENSUS BUILDING, PRACTICE TRANSLATION
Finally, most (82%) respondents reported that they believe their center would be
willing to adopt a centralized informed consent template. More non-US transplant
professionals, said they would be willing to adopt such a template as compared to the US
respondents (84% v. 79%; p =0.001).

DISCUSSION
This study, an international study on informed consent practices during donor
evaluation, reveals that the risks communicated to donors and the informed consent
process vary considerably across transplant professionals, centers and countries. For a
potential donor to truly make an informed choice whether to donate their kidney they
must understand the medical, financial and psychosocial risks they face as compared to
the alternative of not donating their kidney. Patients also need sufficient time to have a
conversation with a health professional, to have risk percentages explained in a way that
makes sense to them, to have education tailored to their level of health literacy, to be
provided with additional materials to take home with them to review and discuss with
their family members, and to be provided with ample opportunity to ask any questions
the may have about the process of donation and risks associated with it.

VARIATION IN RISKS CONVEYED
This study uncovered several important problems that need to be addressed to
improve the living donor informed consent process. First, information about the medical
risks that a potential donor may face is presented to donors at some transplant centers

22
inaccurately. We found, for example, that while 56% of practitioners told potential
donors they had an increased risk of developing ESRD, 40% said that there was no
increased risk or did not discuss the risk at all. Most research available to date indicates
that while GFR does decrease following uninephrectomy, the likelihood of ESRD
requiring dialysis increases only slightly.3, 11, 12 Some research does indicate that the risk
of ESRD does not increase after donation.10, 27, 28 Although the variation in what risks are
conveyed to the reader is probably due to the debate still occurring about what the actual
risks to a living donor are, the result is that potential donors are making donation
decisions based on different risk information depending on the center in which they
undergo transplant evaluation.
Second, discussion of financial and psychosocial outcomes does not always occur
and the conclusions drawn by transplant professionals summarizing the current research
are inconsistent. In this study, and in others, information about financial and
psychosocial risks to the donor was left out about by at least 30% of respondents.25 Even
when discussed, the information communicated to donors varied. For example, although
some research indicates that most donors are satisfied with their donation decision,
current research also consistently shows that worsened familial relations are a possible
but unlikely risk associated with donating a kidney (2 - 13%).14, 19, 29, 30 However, we
found that while a large percentage of practitioners communicated to donors that
donation may negatively affect familial life, many either inform donors that such effects
are not likely or do not discuss this potential risk at all. Similarly, while most respondents
discussed the potential improved psychosocial status of donors, many did not discuss the
risk of donor regret, depression or recollection of the surgery as a traumatic experience.
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Evidence for some risk of these negative psychosocial consequences can be found in the
scientific literature surrounding living kidney donation.20

VARIATION IN DONOR EVALUATION AND INFORMED CONSENT PROCESSES
Inadequate provision of informed consent for prospective organ donors is not
ethically sound clinical practice as it can undermine individuals’ ability to make
autonomous medical decisions. Public awareness of unethical practices can threaten
public trust in the system of transplantation and donation, which in turn, may decrease the
percentage of individuals who volunteer to be living donors.31 In examining differences
in the informed consent process across transplant centers, potential donors may or may
not receive written material about living donor risk by mail, undergo a psychosocial or
medical evaluation of a sufficient duration to get their questions answered, and sign a
donor informed consent document.
Mandatory psychosocial evaluation varied significantly between US and non-US
centers despite an international consensus that psychosocial evaluations are necessary.21,
22, 24, 25, 32, 33

Given the lack of medical benefit to the donor, living kidney donation

continues to spark controversy – within the family, ethicists worry about coercion and
with anonymous donation, ethicists worry about the psychological stability of the donor;
thus a thorough psychosocial evaluation of potential donors is essential in ensuring
donors are in fact making autonomous decisions.17 Given the recent increase in nonrelated donations, and evidence that such evaluations can effectively rule out
psychopathology amongst anonymous donors, this step in the evaluation process should
become standard in all countries.22, 26, 34-37
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Regarding country variation in informed consent processes, it is not clear why US
centers would be more likely to send donors written information prior to donor evaluation
as compared to international transplant centers. However, evidence indicates that having
written material available for donor education prior to donation makes donors more
comfortable with donation.38 Thus, consistently providing written materials to potential
donors may significantly improve the informed consent process. Receiving written
material prior to actual evaluation may also lead to increased donation.
Additionally it is not immediately evident why non-US centers would be more
likely to use specific organ donation consent forms, whereas US centers use more general
surgical consent forms. Perhaps this variation is a result of the US being a more litigious
society and hence less willing to modify basic written forms that have already been
deemed appropriate by the legal system. Alternatively, it could be because as our data
indicates, in the US surgeons are more likely to be responsible for informed consent and
perhaps surgeons are more likely to prefer uniform consent forms for all their surgeries.
Finally, regarding donor follow up, the finding that US centers are less likely to
offer long term follow up for donors may be due to different government policies. The
availability of national health insurance schemes in other countries may facilitate such
follow up for donors. It is not as clear why non-US centers would be less likely to offer
support groups; however, cultural differences may explain this variation. For example, in
most non-Western cultures, patients commonly rely on family members for assistance
with self-care management rather than rely primarily on themselves for their care.39, 40
On the other hand, American health care expects patients to be self reliant after medical
procedures.41 Accordingly, patients in the US may experience additional stress until they
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are fully recovered and thus, may be more amenable to finding comfort in support
groups. While these variations in follow-up and long-term support exist and may be
explained by political and/or cultural differences, there is some evidence that donors,
everywhere, would benefit from access to both long term care and support groups.42
Furthermore, long-term care and follow up will lead to an increase in kidney
donation in two ways. First, potential donors may be more willing to donate if they are
assured that the transplant center will provide them with long-term care. Second, because
of the concerns recipients have for donors, potential recipients may become more willing
to accept kidneys from living donors if they are assured that transplant centers will treat
the health sequelae that result from donating the kidney.4, 19, 42-44 For the reasons above, all
centers should consider providing both long term care and support groups available to
donors.
In the US, the Centers of Medicare and Medicaid Services (CMS) have
implemented conditions of participation that require a broadening of the follow-up and
informed consent practices. As of March 2007, all US transplant centers must follow
donors for 2 years after donor nephrectomy. This initial step should provide for a
clarification on the immediate outcomes following donor nephrectomy; however, longerterm assessment of outcomes following donation can only be obtained through the
creation of a mandatory donor registry, which would track all outcomes of living kidney
donors over the long term.
The informed consent process mandated by CMS and currently developed by the
OPTN/UNOS (Organ Procurement and Transplantation Network/United Network for
Organ Sharing), outlines specific elements that transplant centers must fulfill during the
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informed consent process. This should limit the variability in informed consent processes
that were evident in this survey for US transplant centers. However, follow up surveys of
practices must be conducted to ensure this occurs.

STUDY STRENGTHS AND LIMITATIONS
There were several limitations to our study. First, the survey was only available in
English to attendees of the World Transplant Congress, thus non-English speaking
conference attendees could not participate. As a result of this, it is not evident how
generalizable the results of the survey are. However, sampling of professionals at over
177 transplant centers internationally helps to overcome limitations in generalizability
raised by this concern. It would have been helpful to compare non-responders to
responders using demographic data; however detailed demographic data of all the
Conference attendees were not available. Second, it was not possible to determine a true
response rate for the survey. Given the broad range of WTC attendees including
professionals working in non-kidney transplantation, non-clinician scientists, individuals
working primarily with kidney recipients or with deceased donor kidneys, it was
impossible to estimate the number of attendees who worked primarily with living kidney
donors. Third, although the survey was pilot-tested with experts in transplant and
informed consent issues, it had not been previously validated. Fourth, survey responses
represent self-reported practices, which may not accurately reflect actual informed
consent practices due to social desirability biases and it was not possible to accurately test
how knowledgeable each respondent was about the general practices of their center.
However, knowing that most of the participants spent a significant amount of their time
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working with living donors helps in ensuring some substantial working relationship with
the overall kidney donation program. Fifth, the closed-ended questions of the survey limit
the respondents from providing information about the subtleties of informed consent
practices conducted at their respective centers. Additionally, while nephrologists and
transplant surgeons were overrepresented in the sample population, transplant
coordinators, social workers, and psychologists were underrepresented in the sample.
This disproportionate representation is a concern because the living kidney donor
informed consent process is an iterative team-based process involving all of these
disciplines. Sixth, we did not survey about the risk and duration of prolonged postoperative pain and incapacity. Finally, an individual’s responses may not represent the
true policy of the transplant center, and as with all surveys, the framing of the questions
may lead to inherent biases.

RECOMMENDATIONS:
In summary, the variation in donor informed consent found in this study may be
occurring as a function of not having definitive information about what risks donors face
or due to the increasing pressures of increasing organ availability conflicting with the
ethical obligations of providing complete donor information. Most likely, the variations
in practices are a result of a combination of these two. Our study reinforces and further
develops previous articles that have also indicated significant geographic variation in
informed consent practices.45, 46
We recommend establishing international practice guidelines for informed consent
of living kidney donors. According to our survey results, there is significant interest in a
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uniform informed consent template, and the next step may be to assess what such a
template would actually look like. The benefits of universal guidelines for informed
consent for living donors are numerous, such as reducing healthcare costs and improving
efficiency of clinical practice by avoiding unnecessarily lengthy informed consent
discussions, and ensuring that prospective donors are provided with sufficient
information necessary for adequate decision making, which would reduce the occurrence
of poor decision-making and subsequent low patient satisfaction. Additionally, in legal
cases involving informed consent, courts would have a uniform process to turn to for
evidence of best practices as opposed to relying on the testimony of individual physician
experts. Some disadvantages of having a uniform consent template may include imposing
cultural values and beliefs and foreign concepts onto other cultural groups that do not
share such values and beliefs or concepts. Or conversely, a universal template developed
in the US may not address concerns salient in other cultures.47, 48 Moreover, informed
consent practices are generally shaped by the local health care organizational context in
which they occur, which may therefore hinder standardization.

Overall, however, the development of evidence-based guidelines will help to ensure
that adequate informed consent for living donation is guaranteed for all potential living
donors at transplant centers nationally and internationally. Future research should
ascertain how much time is needed for adequate donor decision making, from whom
donors are most likely to retain risk information, what methods of risk conveyance are
most effective for donor comprehension, and whether variations exist along other
parameters such as size of program or UNOS region.

29

REFERENCES
1. Kim SJ, Gordon EJ, Powe NR. The economics and ethics of kidney transplantation:
Perspectives in 2006. Curr Opin Nephrol Hypertens. 2006;15:593-598.
2. Sommerer C, Morath C, Andrassy J, Zeier M. The long-term consequences of livingrelated or unrelated kidney donation. Nephrol Dial Transplant. 2004;19 Suppl 4:iv45-7.
3. Davis CL, Delmonico FL. Living-donor kidney transplantation: A review of the
current practices for the live donor. J Am Soc Nephrol. 2005;16:2098-2110.
4. Zimmerman D, Albert S, Llewellyn-Thomas H, Hawker GA. The influence of sociodemographic factors, treatment perceptions and attitudes to living donation on
willingness to consider living kidney donor among kidney transplant candidates. Nephrol
Dial Transplant. 2006;21:2569-2576.
5. Herwing-Ulf Meier-Kirsche BK. Advantages of living donor kidney transplantation in
the current era. In: Robert Gaston JW, ed. Living Donor Kidney Transplantation: Current
Practices, Emerging Trends and Evolving Challenges. London: Taylor and Francis;
2005:19.
6. Yang RC, Thiessen-Philbrook H, Klarenbach S, Vlaicu S, Garg AX, Donor
Nephrectomy Outcomes Research (DONOR) Network. Insurability of living organ
donors: A systematic review. Am J Transplant. 2007;7:1542-1551.
7. Clarke KS, Klarenbach S, Vlaicu S, Yang RC, Garg AX, Donor Nephrectomy
Outcomes Research (DONOR) Network. The direct and indirect economic costs incurred
by living kidney donors-a systematic review. Nephrol Dial Transplant. 2006;21:19521960.

30
8. Johnson EM, Najarian JS, Matas AJ. Living kidney donation: Donor risks and quality
of life. Clin Transpl. 1997:231-240.
9. Johnson EM, Anderson JK, Jacobs C, et al. Long-term follow-up of living kidney
donors: Quality of life after donation. Transplantation. 1999;67:717-721.
10. Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of
living kidney donors. Lancet. 1992;340:807-810.
11. Ramcharan T, Matas AJ. Long-term (20-37 years) follow-up of living kidney donors.
Am J Transplant. 2002;2:959-964.
12. Boudville N, Prasad GV, Knoll G, et al. Meta-analysis: Risk for hypertension in
living kidney donors. Ann Intern Med. 2006;145:185-196.
13. Garg AX, Muirhead N, Knoll G, et al. Proteinuria and reduced kidney function in
living kidney donors: A systematic review, meta-analysis, and meta-regression. Kidney
Int. 2006;70:1801-1810.
14. Clemens KK, Thiessen-Philbrook H, Parikh CR, et al. Psychosocial health of living
kidney donors: A systematic review. Am J Transplant. 2006;6:2965-2977.
15. Matas AJ, Bartlett ST, Leichtman AB, Delmonico FL. Morbidity and mortality after
living kidney donation, 1999-2001: Survey of united states transplant centers. Am J
Transplant. 2003;3:830-834.
16. Weitz J, Koch M, Mehrabi A, et al. Living-donor kidney transplantation: Risks of the
donor--benefits of the recipient. Clin Transplant. 2006;20 Suppl 17:13-16.
17. David Orentlicher, Mary Anne Bobinski, Mark Hall. 4. organ transplantation: The
control, use and allocation of body parts. In: Bioethics and Public Health Law. Second
ed. New York, NY: Aspen Publishers; 2008.

31
18. Schostak M, Wloch H, Muller M, et al. Living donor nephrectomy in an open
technique; a long-term analysis of donor outcome. Transplant Proc. 2003;35:2096-2098.
19. Schover LR, Streem SB, Boparai N, Duriak K, Novick AC. The psychosocial impact
of donating a kidney: Long-term follow-up from a urology based center. J Urol.
1997;157:1596-1601.
20. Ingela Fehrman-Ekholm. The pyschosocial impact of donor nephrectomy. In: Robert
Gaston JW, ed. Living Donor Kidney Transplantation: Current Practices, Emerging
Trends and Evolving Challenges. London: Taylor and Francis; 2005:113.
21. Abecassis M, Adams M, Adams P, et al. Consensus statement on the live organ
donor. JAMA. 2000;284:2919-2926.
22. Ethics Committee of the Transplantation Society. The consensus statement of the
amsterdam forum on the care of the live kidney donor. Transplantation. 2004;78:491492.
23. Eggeling C. The psychosocial implications of live-related kidney donation. EDTNA
ERCA J. 1999;25:19-22.
24. Adams PL, Cohen DJ, Danovitch GM, et al. The nondirected live-kidney donor:
Ethical considerations and practice guidelines: A national conference report.
Transplantation. 2002;74:582-589.
25. Rodrigue JR, Pavlakis M, Danovitch GM, et al. Evaluating living kidney donors:
Relationship types, psychosocial criteria, and consent processes at US transplant
programs. Am J Transplant. 2007;7:2326-2332.
26. Mandelbrot DA, Pavlakis M, Danovitch GM, et al. The medical evaluation of living
kidney donors: A survey of US transplant centers. Am J Transplant. 2007;7:2333-2343.

32
27. Narkun-Burgess DM, Nolan CR, Norman JE, Page WF, Miller PL, Meyer TW. Fortyfive year follow-up after uninephrectomy. Kidney Int. 1993;43:1110-1115.
28. Fehrman-Ekholm I, Elinder CG, Stenbeck M, Tyden G, Groth CG. Kidney donors
live longer. Transplantation. 1997;64:976-978.
29. Jacobs C, Johnson E, Anderson K, Gillingham K, Matas A. Kidney transplants from
living donors: How donation affects family dynamics. Adv Ren Replace Ther. 1998;5:8997.
30. Westlie L, Fauchald P, Talseth T, Jakobsen A, Flatmark A. Quality of life in
norwegian kidney donors. Nephrol Dial Transplant. 1993;8:1146-1150.
31. Ohler L. Organ transplantation and the media: The good, the bad, and the ugly. J
Transpl Coord. 1997;7:52-53.
32. Dew MA, Jacobs CL, Jowsey SG, et al. Guidelines for the psychosocial evaluation of
living unrelated kidney donors in the united states. Am J Transplant. 2007;7:1047-1054.
33. Fisher MS S. Psychosocial evaluation interview protocol for living related and living
unrelated kidney donors. Soc Work Health Care. 2003;38:39-61.
34. Jendrisak MD, Hong B, Shenoy S, et al. Altruistic living donors: Evaluation for
nondirected kidney or liver donation. Am J Transplant. 2006;6:115-120.
35. Burley JA, Stiller CR. Emotionally related donors and renal transplantation.
Transplant Proc. 1985;17:123-127.
36. Kluge EH. Designated organ donation: Private choice in social context. Hastings
Cent Rep. 1989;19:10-16.
37. Truog RD. The ethics of organ donation by living donors. N Engl J Med.
2005;353:444-446.

33
38. Waterman AD, Covelli T, Caisley L, et al. Potential living kidney donors' health
education use and comfort with donation. Prog Transplant. 2004;14:233-240.
39. Becker G, Beyene Y, Newsom EM, Rodgers DV. Knowledge and care of chronic
illness in three ethnic minority groups. Fam Med. 1998;30:173-178.
40. Galanti G. Caring for Patients from Different Cultures: Case Studies from American
Hospitals. 2nd ed. Philadelphia: University of Pennsylvania Press; 1997.
41. Minkler M. Personal responsibility for health? A review of the arguments and the
evidence at century's end. Health Educ Behav. 1999;26:121-140.
42. Cabrer C, Oppenhaimer F, Manyalich M, et al. The living kidney donation process:
The donor perspective. Transplant Proc. 2003;35:1631-1632.
43. Gordon EJ. "They don't have to suffer for me": Why dialysis patients refuse offers of
living donor kidneys. Med Anthropol Q. 2001;15:245-267.
44. Waterman AD, Stanley SL, Covelli T, Hazel E, Hong BA, Brennan DC. Living
donation decision making: Recipients' concerns and educational needs. Prog Transplant.
2006;16:17-23.
45. Housawi AA, Young A, Boudville N, et al. Transplant professionals vary in the longterm medical risks they communicate to potential living kidney donors: An international
survey. Nephrol Dial Transplant. 2007.
46. Lennerling A, Nyberg G. Written information for potential living kidney donors.
Transpl Int. 2004;17:449-452.
47. Marshall P. A. "The relevance of culture for informed consent in U.S. funded
international health research." In: NBAC, ed. Ethical and Policy Issues in International
Research: Clinical Trials in Developing Countries, Volume II: Commissioned Papers

34
and Staff Analysis.. Vol II. Bethesda, MD: National Bioethics Advisory Commission;
2001:C1.
48. Christakis NA. Ethics are local: Engaging cross-cultural variation in the ethics for
clinical research. Soc Sci Med. 1992;35:1079-1091.

